novo nordisk eli lilly

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 3d · on MSN

· 2d

Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

· 13d · on MSN

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Novo Nordisk Inks A Major Obesity Deal

Digest more

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Fierce Biotech · 1d

BioSpace · 1d

Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B

Zacks Investment Research on MSN · 11h

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 18h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

Money Morning1d

Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it?

1don MSN

Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently.

Novo Nordisk: A Strategy With High Potential For Volatile Times

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

pharmaphorum2d

Novo Nordisk builds case for Norditropin successor

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as effective as a daily shot of Norditropin (somatropin) in children born small for gestational age (SGA), Noonan syndrome (NS), or with idiopathic short stature (ISS).